# Mankind Pharma Q2 profit surges up to 39% to ₹712 crore 2026-10-26T12:57:35+00:00 | Business & Economy | Indian Opinion Desk Corroboration: 4 independent outlets Mankind Pharma reported a 37.7% to 39.2% year-on-year rise in consolidated net profit for the September quarter, with CNBCTV18 putting the figure at ₹712 crore while The Hans India and Business Standard report ₹716 crore. Revenue from operations grew 17.3% to ₹4,338 crore, driven by strong domestic business growth of 15.9% and a 33% jump in international revenue, supported by the specialty portfolio of Bharat Serums and Vaccines. Vice Chairman Rajeev Juneja said the firm’s recent acquisition of Armed Cell Therapeutics marks its entry into next-generation CAR-T therapies. The consumer healthcare business posted muted 1.2% growth amid slower category offtake. The board also approved schemes to merge wholly owned subsidiaries Prolijune Lifesciences and Pavi Buildwell into the parent, with an appointed date of April 1, 2027, subject to NCLT and regulatory approvals. Shares rose over 3% on the BSE on October 26. ## Indian Opinion Analysis All four sources report Mankind Pharma’s Q2 profit jump of roughly 37 to 39% and revenue rise of 17%, with factual figures that align closely. CNBCTV18 leads with the exact profit figure of ₹712 crore and the 39% rise, while The Hans India and Business Standard report ₹716 crore and 37.7%, a minor difference in rounding. CNBCTV18 emphasises the merger plans for its subsidiaries and the board’s approval, whereas The Hans India and Business Standard quote Vice Chairman Rajeev Juneja on the Armed Cell Therapeutics acquisition and CAR-T therapy entry. The Economic Times provides the deepest breakdown, including brand-wise growth, prescription share, and consumer healthcare segment weakness. ## Coverage Coverage: 4 sources, 4 neutral - cnbctv18.com (neutral report) Leads with exact profit figure and merger details - economictimes.indiatimes.com (neutral report) Deep segmental breakdown, brand performance focus - thehansindia.com (neutral report) Brief summary with one executive quote on CAR-T entry - business-standard.com (neutral report) Concise report on chronic drug demand and OTC drag This brief was synthesised by AI from the 4 sources linked above, so one read covers every framing they carry. Tags: Bharat Serums and Vaccines, Mankind Pharma, National Company Law Tribunal, Rajeev Juneja Canonical: https://indianopinion.org/mankind-pharma-q2-profit-surges-up-to-39-to-rs712-crore/ License: Summary and commentary (c) Indian Opinion, reusable with attribution. Facts belong to the linked sources. Cite: https://indianopinion.org/mankind-pharma-q2-profit-surges-up-to-39-to-rs712-crore/#story-in-brief How this brief was made: an AI model read the reports linked above and wrote this summary and analysis, which were published automatically. Published briefs are sampled every hour by an automated quality check; the editor verifies its findings and approves corrections, and corrected briefs carry a dated correction line. Stance labels are editorial classifications of how each outlet framed this story, assigned by the same model, not ratings of the outlets. We do no original reporting. Methodology: https://indianopinion.org/ai-use-policy/